This Surging Biotech Company Has Attracted a Web of Hedge Fund Managers

Several big-name hedge funds are enjoying gains from Axovant Sciences, whose parent company was founded by a former hedge fund manager.

Fraser Wright (Photo via Spark Therapeutics)

Fraser Wright

(Photo via Spark Therapeutics)

A small clinical-stage biotech company that more than doubled in price on Wednesday had previously attracted a large group of high-profile hedge fund managers.

Shares of Axovant Sciences surged 160 percent, to close at $4.55, on Wednesday after the company announced it licensed the exclusive worldwide rights to develop and commercialize an investigational gene therapy for Parkinson’s disease from Oxford BioMedica.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.